SIRT1 and neoplasm: This is why NF-κB is a target for many anti-tumor drugs, which generally work by increasing the expression and activity of SIRT1 (El-Kott et al., 2021; Zhang et al., 2014; Zhou et al., 2019; Buhrmann et al., 2016).